Deep hypothermic circulatory arrest (DHCA) is a technique of extracorporeal circulation commonly used in children with complex congenital heart defects undergoing surgical repairs. The use of profound cooling (20°C) and complete cessation of circulation allow adequate exposure and correction of these complex lesions, with enhanced cerebral protection. However, the profound physiologic state of DHCA results in significant derangement of the coagulation system and a high incidence of postoperative bleeding. This review examines the impact of DHCA on bleeding and transfusion requirements in children and the pathophysiology of DHCA-induced platelet dysfunction. It also focuses on possible pharmacologic interventions to decrease bleeding following DHCA in children.
Sullivan MT, Wallace EL.Blood collection and transfusion in the United States in 1999. Transfusion. 2005;45: 141-148.
2.
Nightingale S, Wanamaker V, Silverman B, et al. Use of sentinel sites for daily monitoring of the US blood supply. Transfusion. 2003;43:364-372.
3.
Goodnough LT, Despotis GJ.Transfusion Medicine: support of patients undergoing cardiac surgery. Am J Cardiovasc Drugs. 2001;1:337-351.
4.
Manno CS, Hedberg KW, Kim HC, et al. Comparison of the hemostatic effects of fresh whole blood, stored whole blood and components after open heart surgery in children. Blood. 1991;77:930-936.
5.
Mou SS, Giroir BP, Molitor-Kirsch EA, et al. Fresh whole blood versus reconstituted blood for pump priming in heart surgery in infants. N Engl J Med. 2004; 351:1635-1644.
6.
Williams GD, Bratton SL, Ramamoorthy C.Factors associated with blood loss and blood product transfusions: a multivariate analysis on children after open-heart surgery. Anesth Analg. 1999;89:57-64.
7.
Williams GD, Bratton SL, Riley EC, et al. Coagulation tests during cardiopulmonary bypass correlate with blood loss in children undergoing cardiac surgery. J Cardiothorac Vasc Anesth. 1999;13:398-404.
8.
DiNardo J.Physiology and techniques of extracorporeal circulation in the Pediatric Patient. In: Lake CL, Booker PD, eds. Pediatric Cardiac Anesthesia. 4th ed.Philadelphia: Lippincott Williams & Wilkins; 2005:228-252.
9.
Boldt J, Knothe C, Zickmann B, et al. Comparison of two aprotinin dosage regimens in pediatric patients having cardiac operations. Influence on platelet function and blood loss. J Thorac Cardiovasc Surg. 1993;105:705-711.
10.
Boldt J, Knothe C, Zickmann B, et al. Aprotinin in pediatric cardiac operations: platelet function, blood loss and use of homologous blood. Ann Thorac Surg. 1993; 55:1460-1466.
11.
van Oeveren, W, Jansen NJ, Bidstrup BP, et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg. 1987;44:640-645.
12.
Andrew M, Vegh P, Johnston M, et al. Maturation of the hemostatic system during childhood. Blood. 1992;80:1998-2005.
13.
Tempe DK, Virmani S.Coagulation abnormalities in patients with cyanotic congenital heart disease. J Cardiothorac Vasc Anesth. 2002;16:752-765.
14.
Ekert H, Gilchrist GS, Stanton R, et al. Hemostasis in cyanotic congenital heart disease. J Pediatr. 1970;76:221-230.
15.
Kern FH, Morana NJ, Sears JJ, et al. Coagulation defects in neonates during cardiopulmonary bypass. Ann Thorac Surg. 1992;54:541-546.
16.
Horkay F, Martin P, Rajah M, et al. Response to heparinization in adults and children undergoing cardiac operations. Ann Thorac Surg. 1992;53:822-826.
17.
Khuri SF, Valeri CR, Loscalzo J, et al. Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. Ann Thorac Surg. 1995;60:1008-1014.
18.
Kestin AS, Valeri CR, Khuri SF, et al. The platelet function defect of cardiopulmonary bypass. Blood. 1993;82:107-117.
19.
Xiao Z, Theroux P.Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation. 1998;97:251-256.
20.
Kozek-Langenecker SA, Mohammad SF, Masaki T, et al. The effects of heparin, protamine, and heparinase 1 on platelets in vitro using whole blood cytometry. Anesth Analg. 2000;90:808-812.
21.
Muriithi EW, Belcher PR, Rao JN, et al. The effects of heparin and extracorporeal circulation on platelet counts and platelet microaggregation during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2000;120:538-543.
22.
Muriithi EW, Belcher PR, Day SP, et al. Heparin-induced platelet dysfunction and cardiopulmonary bypass. Ann Thorac Surg. 2000;69:1827-1832.
23.
Muriithi EW, Belcher PR, Day SP, et al. Lipolysis generates platelet dysfunction after in vivo heparin administration. Clin Sci (Lond). 2002;103:433-440.
24.
Paparella D, Brister SJ, Buchanan MR.Coagulation disorders of cardiopulmonary bypass: a review. Intensive Care Med. 2004;30:1873-1881.
25.
Green JA, Spiess BD.Current status of antifibrinolytics in cardiopulmonary bypass and elective deep hypothermic circulatory arrest. Anesthesiol Clin North America. 2003;21:527-551.
26.
Despotis GJ, Joist JH, Hogue CW Jr, et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg. 1995;110:46-54.
27.
Despotis GJ, Joist JH, Hogue CW Jr, et al. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost. 1996;76:902-908.
28.
Jobes DR, Aitken GJ, Shaffer GW.Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. J Thorac Cardiovasc Surg. 1995;110:36-45.
29.
Despotis GJ, Filos KS, Zoys TN, et al. Factors associated with excessive post-operative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients. Anesth Analg. 1996;82:13-21.
30.
Ammar T, Fisher C.The effects of heparinase-1 and protamine on platelet reactivity. Anesthesiology. 1997;86: 1382-1386.
31.
Shigeta O, Kojima H, Hiramatsu Y, et al. Low-dose protamine based on heparin-protamine titration method reduces platelet dysfunction after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1999;118:354-360.
32.
Mochizuki T, Olson PJ, Szlam F, et al. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg. 1998;87:781-785.
33.
Michelson AD, MacGregor H, Barnard MR, et al. Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro. Thromb Haemost. 1994;71:633-640.
34.
Valeri CR, Khabbaz K, Khuri SF, et al. Effect of skin temperature on platelet function in patients undergoing extracorporeal bypass. J Thorac Cardiovasc Surg. 1992;104: 108-116.
35.
Boldt J, Knothe C, Welters I, et al. Normothermic versus hypothermic cardiopulmonary bypass: do changes in coagulation differ?Ann Thorac Surg. 1996;62:130-135.
36.
Mazer CD, Hornstein A, Freedman J.Platelet activation in warm and cold heart surgery. Ann Thorac Surg. 1995;59:1481-1486.
37.
Lindenblatt N, Menger MD, Klar E, et al. Sustained hypothermia accelerates microvascular thrombus formation in mice. Am J Physiol (Heart Circ Physiol). 2005;289:H2680-H2687.
38.
Faraday N, Rosenfeld BA.In vitro hypothermia enhances platelet GPIIb/IIIa activation and P-selectin expression. Anesthesiology. 1998;88:1579-1585.
39.
Hall MW, Goodman PD, Alston SM, et al. Hypothermiainduced platelet aggregation in heparinized flowing human blood: identification of a high responder subpopulation. Am J Hematology. 2002;69:45-55.
40.
Hall MW, Hopkins RO, Long JW, et al. Hypothermiainduced platelet aggregation and cognitive decline in coronary artery bypass surgery: a pilot study. Perfusion. 2005;20:157-167.
41.
Fergusson D, Glass KC, Hutton B, et al. Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding?Clin Trials. 2005;2: 218-232.
42.
Laupacis A, Fergusson D.Drugs to minimize perioperative blood loss in cardiac surgery: meta-analysis using perioperative blood transfusion as the outcome. Anesth Analg. 1997;85:1258-1267.
43.
Bennett-Guerrero E, Sorohan JG, Gurevich ML, et al. Cost-benefit and efficacy of aprotinin compared with epsilon-aminocaproic acid in patients having repeated cardiac operations: a randomized, blinded clinical trial. Anesthesiology. 1997;87:1373-1380.
44.
Vander Salm TJ, Kaur S, Lancey RA, et al. Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid. J Thorac Cardiovasc Surg. 1996;112:1098-1107.
45.
Sedrakyan A, Treasure T, Elefteriades JA.Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg. 2004;128: 442-448.
46.
Poullis M, Manning R, Laffan M, et al. The antithrombotic effect of aprotinin: actions mediated via the protease-activated receptor-1. J Thorac Cardiovasc Surg. 2000;120:370-378.
47.
Despotis GJ, Avidan MS, Hogue Jr.Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg. 2001;72:S1821-S1831.
48.
Eaton MP, Deeb GM.Aprotinin versus epsilon-aminocaproic acid for aortic surgery using deep hypothermic circulatory arrest. J Cardiothorac Vasc Anesth. 1998;12: 548-552.
49.
Ben Mime L, Arnhold S, Fischer JH, et al. Pharmacologic cerebral capillary blood flow improvement after deep hypothermic circulatory arrest: an intravital fluorescence microscopy study in pigs. J Thorac Cardiovasc Surg. 2005;130:670-676.
50.
Straub A, Azevedo R, Beierlein W, et al. Glycoprotein IIb/IIIa inhibition reduces prothrombotic events under conditions of deep hypothermic circulatory arrest. Thromb Haemost. 2005;94:115-122.
51.
Straub A, Azevedo R, Beierlein W, et al. Hypothermiainduced platelet aggregation: no effect of aprotinin (trasylol) but inhibition by eptifibatide (integrelin). Thorac Cardiovasc Surg. 2005;53:80-84.
52.
Rubens, FD, Sabloff M, Wells PS, et al. Use of recombinant-hirudin in pulmonary thromboendarterectomy. Ann Thorac Surg. 2000;69:1942-1943.
53.
Koster A, Sanger S, Knorig J, et al. Autologous plasma and platelet sequestration at the beginning of cardiopulmonary bypass: a pilot investigation in five patients undergoing extended vascular surgery in deep hypothermia. ASAIO J. 2002;48:106-109.
54.
Mossinger H, Dietrich W.Activation of hemostasis during cardiopulmonary bypass and pediatric aprotinin dosage. Ann Thorac Surg. 1998;65(6 suppl):S45-S50.
55.
Chan AK, Leaker M, Burrows FA, et al. Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass. Thromb Haemost. 1997;77: 270-277.
56.
Pang LM, Stalcup SA, Lipset JS, et al. Increased circulating bradykinin during hypothermia and cardiopulmonary bypass in children. Circulation. 1979;60:1503-1507.
57.
Smith CR, Spanier TB.Aprotinin in deep hypothermic circulatory arrest. Ann Thorac Surg. 1999;68:278-286.
58.
Horrow J.Transfusion medicine and coagulation disorders. In: Kaplan JA, ed. Cardiac Anesthesia. Philadelphia: WB Saunders; 1987:111-1154.
59.
Nagaoka H, Katori M.Inhibition of kinin formation by a kallikrein inhibitor during extracorporeal circulation in open-heart surgery. Circulation. 1975;52:325-332.
60.
Blauhut B, Gross C, Necek S, et al. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1991;101:958-967.
61.
Tabuchi N, DeHann J, Boonstra PW, et al. Aprotinin effect on platelet function and clotting during cardiopulmonary bypass. Eur J Cardiothorac Surg. 1994;8:87-90, 1994
62.
Huang H, Ding W, Su Z, et al. Mechanism of the preserving effect of aprotinin on platelet function and its use in cardiac surgery. J Thorac Cardiovasc Surg. 1993;106:11-18.
63.
Shigeta O, Kojima H, Jikuya T, et al. Aprotinin inhibits plasmin-induced platelet activation during cardiopulmonary bypass. Circulation. 1997;96:569-574.
64.
Dietrich W.Reducing thrombin formation during cardiopulmonary bypass: is there a benefit of the additional anticoagulant action of aprotinin?J Cardiovasc Pharmacol. 1996;27(suppl 1):S50-S57.
65.
John LC, Rees GM, Kovacs IB.Reduction of heparin binding to and inhibition of platelets by aprotinin. Ann Thorac Surg. 1993;55:1175-1179.
66.
Landis RC, Asimakopoulos G, Poullis M, et al. The antithrombotic and antiinflammatory mechanisms of action of aprotinin. Ann Thorac Surg. 2001;72:2169-2175.
67.
Landis RC, Haskard DO, Taylor KM.New antiinflammatory and platelet-preserving effects of aprotinin. Ann Thorac Surg. 2001;72:S1808-S1813.
68.
Elliott MJ, Allen A.Aprotinin in pediatric cardiac surgery. Perfusion. 1990;5:73-76.
69.
Popov-Cenic S, Urban AE, Noe G.Studies on the cause of bleeding during and after surgery with heart-lung-machine in children with cyanotic and acyanotic congenital cardiac defects and their prophylactic treatment. In: McConn R, ed. Role of Chemical Mediators in the Pathophysiology of Acute Illness Injury. New York: Raven; 1982:229-242.
70.
Penkoske PA, Entwistle LM, Marchak BE, et al. Aprotinin in children undergoing repair of congenital heart defects. Ann Thorac Surg. 1995;60:S529-S532.
71.
Royston D.Pro. Aprotinin should be used in patients undergoing hypothermic circulatory arrest. J Cardiothorac Vasc Anesth. 2001;15:121-125.
72.
Mossinger H, Dietrich W, Braun SL, et al. High-dose aprotinin reduces activation of hemostasis, allogeneic blood requirement, and duration of postoperative ventilation in pediatric cardiac surgery. Ann Thorac Surg. 2003;75:430-437.
73.
Dietrich W, Mossinger H, Spannagl M, et al. Hemostatic activation during cardiopulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations. J Thorac Cardiovasc Surg. 1993;105:712-720.
74.
Oliver WC, Fass DN, Nuttall GA, et al. Variability of plasma aprotinin concentrations in pediatric patients undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2004;127:1670-1677.
75.
Mossinger HD, Spannagel M.Influence of aprotinin on coagulation patterns and blood loss in infants undergoing surgery for congenital heart defects [abstract]. Anesthesiology. 1991;75:A77-A77.
76.
Tweddell JS, Hoffman GM, Mussatto KA, et al. Improved survival of patients undergoing palliation of hypoplastic left heart syndrome: lessons learned from 115 consecutive patients. Circulation. 2002;106(12 suppl 1):I82-I89.
77.
Costello JM, Backer CL, deHoyos A, et al. Aprotinin reduces operative closure time and blood product use after pediatric bypass. Ann Thorac Surg. 2003;75:1261-1266.
78.
D'Errico CC, Shayevitz JR, Martindale SJ, et al. The efficacy and cost of aprotinin in children undergoing reoperative open heart surgery. Anesth Analg. 1996;83:1193-1199.
79.
D'Errico CC.Pharmacoeconomics analysis in a pediatric population. Ann Thorac Surg. 1998;65(6 suppl):S52-S54.
80.
Aoki M, Jonas RA, Nomura F, et al. Effects of aprotinin on acute recovery of cerebral metabolism in piglets after hypothermic circulatory arrest. Ann Thorac Surg. 1994;58: 146-153.
81.
Mangano DT, Tudor IC, Dietzel C, et al. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006;354:353-365.
82.
Mora Mangano CT, Neville MJ, Hsu PH, et al. Aprotinin, blood loss, and renal dysfunction in deep hypothermic circulatory arrest. Circulation. 2001;104(12 suppl 1):I276-I281.
83.
Sedrakyan A, Treasure T, Elefteriades JA.Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg. 2004;128:442-448.
84.
Pouard P.Review of efficacy parameters. Ann Thorac Surg. 1998;65(suppl 6):S40-S43.
85.
Dietrich W, Spath P, Ebell A, et al. Prevalence of anaphylactic reactions to aprotinin: analysis of two hundred forty-eight reexposures to aprotinin in heart operations. J Thorac Cardiovasc Surg. 1997;113:194-201.
86.
Jaquiss RD, Ghanayem NS, Zacharisen MC, et al. Safety of aprotinin use and re-use in pediatric cardiothoracic surgery. Circulation. 2002;106(12 suppl 1):I90-I94.
87.
Williams GD, Bratton SL, Nielsen NJ, et al. Fibrinolysis in pediatric patients undergoing cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 1998;12:633-638.
88.
Ries M, Zenker M, Gaffney PJ.Differences between neonates and adults in the urokinase-plasminogen activator (u-PA) pathway of the fibrinolytic system. Thromb Res. 2000;100:341-351.
89.
Chauhan S, Kumar BA, Rao BH, et al. Efficacy of aprotinin, epsilon aminocaproic acid, or combination in cyanotic heart disease. Ann Thorac Surg. 2000;70:1308-1312.
90.
Bulutcu FS, Ozbek U, Polat B, et al. Which may be effective to reduce blood loss after cardiac operations in cyanotic children: tranexamic acid, aprotinin or a combination?Paediatr Anaesth. 2005;15:41-46.
91.
Chauhan S, Das SN, Bisoi A, et al. Comparison of epsilon aminocaproic acid and tranexamic acid in pediatric cardiac surgery. J Cardiothorac Vasc Anesth. 2004; 18:141-143.
92.
Reid RW, Zimmerman AA, Laussen PC, et al. The efficacy of tranexamic acid versus placebo in decreasing blood loss in pediatric patients undergoing repeat cardiac surgery. Anesth Analg. 1997;84:990-996.
93.
Gruber EM, Shukla AC, Reid RW, et al. Synthetic antifibrinolytics are not associated with an increased incidence of baffle fenestration closure after the modified Fontan procedure. J Cardiothorac Vasc Anesth. 2000;14:257-259.
94.
Andersson TLG, Solem JO, Tengborn L, et al. Effects of desmopressin acetate on platelet aggregation, von Willebrand factor, and blood loss after cardiac surgery with extracorporeal circulation. Circulation. 1990;81:872-878.
95.
Cattaneo M, Harris AS, Stromberg U, et al. The effect of desmopressin on reducing blood loss in cardiac surgery— a meta-analysis of double-blind, placebo-controlled trials. Thromb Haemost. 1995;74:1064-1070.
96.
Oliver WC, Santrach PJ, Danielson GK, et al. Desmopressin does not reduce bleeding and transfusion requirements in congenital heart operations. Ann Thorac Surg. 2000;70:1923-1930.
97.
Razon Y, Erez E, Vidne B, et al. Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease. Paediatr Anaesth. 2005; 15:235-240.
98.
Tobias JD, Simsic JM, Weinstein S, et al. Recombinant factor VIIa to control excessive bleeding following surgery for congenital heart disease in pediatric patients. J Intensive Care Med. 2004;19:270-273.
99.
Wittenstein B, Ng C, Ravn H, et al. Recombinant factor VII for severe bleeding during extracorporeal membrane oxygenation following open heart surgery. Pediatr Crit Care Med. 2005;6:473-476.
100.
Karkouti K, Beattie WS, Wijeysundera DN, et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion. 2005;45:26-34.
101.
Dietrich W, Spannagl M.Caveat against the use of activated recombinant factor VII for intractable bleeding in cardiac surgery. Anesth Analg. 2002;94:1369-1371.
